JCR Pharmaceuticals Co., Ltd.
Stock Price Chart
2026/03/02 UpdatedPrice Trend
2026/03/02 UpdatedPrice & Trading Details
2026/03/02 UpdatedPRICE
TRADING
Analyst Recommendations 6 analysts
Updated 2026/03/01Shareholder Composition
Updated 2026/03/01Top Mutual Funds / ETFs
Updated 2026/03/01Major Holders
Updated 2026/03/01| Fund Name | Ownership | Shares | Change |
|---|---|---|---|
|
VANGUARD STAR FUNDS-Vanguard Total International Stock Index Fund
|
952.9K | 0.00% | |
|
VANGUARD TAX-MANAGED FUNDS-Vanguard Developed Markets Index Fund
|
599.8K | +8.38% | |
|
American Century ETF Trust-Avantis International Small Cap Value ETF
|
368.7K | 0.00% | |
|
VANGUARD Intl Eqy. INDEX Fd.S-Vanguard FTSE All-World ex-US Small-Cap
|
238.6K | +17.08% | |
|
SCHWAB STRATEGIC TRUST-Schwab International Small-Cap Equity ETF
|
136.6K | +8.23% | |
|
VANGUARD Intl Eqy. INDEX Fd.S-Vanguard Pacific Stock Index Fd.
|
81.8K | 0.00% |
| Institution | Ownership | Shares | Change |
|---|---|---|---|
|
Legato Capital Management LLC
|
10.9K | +1.00% |
Dividend History
Updated 2026/03/01| Year | Dividend | Change |
|---|---|---|
| 2025 | ¥20 | 0.0% |
| 2024 | ¥20 | 0.0% |
| 2023 | ¥20 | -9.1% |
| 2022 | ¥22 | +46.7% |
| 2021 | ¥15 | - |
Financial Performance
2026/03/01 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | ¥51,082M | ¥34,343M | ¥42,871M | ¥33,072M |
| Gross Profit | ¥40,620M | ¥25,456M | ¥31,251M | ¥21,738M |
| Operating Income | ¥19,934M | ¥4,976M | ¥7,532M | -¥6,651M |
| Pretax Income | ¥19,449M | ¥5,456M | ¥7,330M | -¥6,259M |
| Net Income | ¥14,507M | ¥3,772M | ¥5,507M | -¥4,759M |
| EPS | ¥116.80 | ¥30.22 | ¥43.92 | - |
| Operating Margin | 39.02% | 14.49% | 17.57% | -20.11% |
| Balance Sheet | ||||
| Total Assets | ¥97,134M | ¥94,937M | ¥102,226M | ¥104,855M |
| Total Equity | ¥50,881M | ¥52,161M | ¥56,176M | ¥47,040M |
| Total Liabilities | ¥46,253M | ¥42,776M | ¥46,050M | ¥57,815M |
| Cash | ¥30,733M | ¥13,278M | ¥18,756M | ¥13,196M |
| Interest-bearing Debt | ¥18,100M | ¥22,800M | ¥23,300M | ¥38,105M |
| Equity Ratio | 52.38% | 54.94% | 54.95% | 44.86% |
| D/E Ratio | 0.36 | 0.44 | 0.41 | 0.81 |
| Cash Flow | ||||
| Operating CF | ¥9,289M | -¥5,500M | ¥9,312M | -¥5,486M |
| Investing CF | -¥3,250M | -¥15,002M | -¥2,690M | -¥9,874M |
| Financing CF | -¥2,179M | ¥1,948M | -¥2,031M | ¥9,736M |
| Free CF | -¥2,118M | -¥14,060M | ¥7,786M | -¥15,374M |
| Efficiency | ||||
| ROE | 28.51% | 7.23% | 9.80% | -10.12% |
| ROA | 14.94% | 3.97% | 5.39% | -4.54% |
Latest IR Information
-
Notice Regarding Changes in Representative Directors, Organizational Restructuring, Executive Personnel Changes, and Personnel Transfers
Effective April 1, 2026, changes will be made to the representative directors, multiple new organizations including the President’s Office and Advanced Biopharmaceutical Research Institute will be established or restructured, and personnel changes for executives and executive officers will be implemented.
Read more -
Financial Summary for Q3 Fiscal Year Ending March 2026 [Japanese GAAP] (Consolidated)
For Q3 of the fiscal year ending March 2026, net sales were ¥30,353 million (up 17.3% YoY), operating income was ¥427 million, and net income attributable to owners of parent for the quarter was ¥1,744 million.
Read more -
Notice Regarding Revision of Full-Year Consolidated Earnings Guidance
The sales forecast for the fiscal year ending March 2026 has been revised upward to ¥39.5 billion (4.5% increase from previous forecast), while operating income was revised downward to ¥400 million (84.6% decrease), and net income attributable to owners of...
Read more -
FY March 2026 Q3 Earnings Presentation
For the third quarter of FY March 2026, net sales were 30,353 million yen, a 17.3% increase year-over-year. Operating income turned positive to 427 million yen. Full-year earnings guidance was revised to net sales of 39,500 million yen and operating...
Read more -
Notice of Recording Special Income (Grant Income)
Recorded a special income of 1,882 million yen from a grant by the Ministry of Health, Labour and Welfare in the third quarter of the fiscal year ending March 2026.
Read more
Latest News (5 items)
-
Average Analyst Rating: none
Average Target Price: ¥692
Rating Score: 3.33 (Based on 6 analysts)
※1=Strong Buy, 5=Strong Sell
Company Information
About
JCR Pharmaceuticals Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, import and export, and sale of pharmaceutical products, regenerative medicines, and drug substances in Japan. It offers various therapeutic products, including GROWJECT used for the treatment of growth hormone deficiency and short stature; IZCARGO to treat Mucopolysaccharidosis type II; Agalsidase Beta BS I.V. Infusion used for the treatment of Fabry disease; and TEMCELL HS Inj used to treat acute graft-versus-host disease. The company develops Epoetin Alfa BS and Darbepoetin Alfa BS Injections for the treatment of renal anemia. In addition, it sells, imports, and exports medical devices; and purchases and sells medical and research equipment. The company has a collaboration agreement with Angelini Pharma for the development of novel biologic therapies; and a. joint research agreement with Modalis Therapeutics Corporation to evaluate the drug delivery technology of the gene therapy to the central nervous system (CNS) assuming CNS diseases as a target. The company was founded in 1975 and is based in Ashiya, Japan.
